問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2014-07-01 - 2023-10-25

Phase III

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated4Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2014-07-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2014-09-01 - 2019-11-30

Phase II

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablets

Participate Sites
5Sites

Terminated5Sites

2015-07-01 - 2020-12-31

Phase III

A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy ≥1 month to <4 years of age with partial-onset seizures

  • Condition/Disease

    partial-onset seizures

  • Test Drug

    VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

2015-03-01 - 2019-04-30

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

  • Condition/Disease

    with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates

  • Test Drug

    SGI-110 for subcutaneous injection

Participate Sites
7Sites

Terminated5Sites

高志平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2014-11-01 - 2016-12-31

Phase II

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    GS-4774 Powder for Suspension for Injection

Participate Sites
3Sites

Terminated3Sites

2015-09-01 - 2018-12-31

Phase II

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Durvalumab (MEDI4736), Tremelimumab

Participate Sites
3Sites

Terminated3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-04-01 - 2018-12-31

Phase III

a double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy

  • Condition/Disease

    idiopathic generalized epilepsy

  • Test Drug

    VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

周宜卿
China Medical University Hospital-Taipei

未分科

2015-09-09 - 2017-11-30

Phase III

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinumdoublet Chemotherapy

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablet

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-07-01 - 2018-12-01

Phase II

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    MEDI4736

Participate Sites
5Sites

Terminated5Sites

1 252 253 254 255 256 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB